← Leaderboards
Robert M Sharkey
Ctr For Molecular Medicine/Immunology
$7,941,617
Attributed
$7,941,617
Total exposure
15
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–09$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$7,941,617 · 15
By mechanism
R01$6,337,356 · 6
P01$1,098,751 · 8
C06$505,510 · 1
Top collaborators
No co-investigators on record.
Most similar at Ctr For Molecular Medicine/Immunology
Same institution · by research overlap
- David M Goldenberg$649,937
- David V Gold$4,477,124
- Rosalyn D Blumenthal$4,498,008
- M Jules Mattes$1,208,134
Others in their field
Top investigators on “Monoclonal Antibody”
- Bambra Strokes · Ppd Development Lp$461,655,950
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$276,346,332
- Lawrence Corey · Fred Hutchinson Cancer Center$271,417,082
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$257,261,947
- Peter B. Gilbert · Fred Hutchinson Cancer Center$190,281,881
- Barton F Haynes · Duke University$125,632,198
Research focus
Monoclonal AntibodyClinical ResearchAntitumor AntibodyImmunoglobulin GRadiotracerProceduresTumorBaseAntibodiesPropertyPeptidesDoseXenograft ProcedureConditionToxic EffectRadioactivityAntibodies, BispecificRadiationRadiolabeledLabelPharmacokineticsClinical TrialsDose-LimitingDrug Kinetics
Grant awards (23)
Bispecific Antibody Pretargeting for Therapy$582,397
R01 · FY2009 · CA · contact PI
Bispecific Antibody Pretargeting for Therapy$512,569
R01 · FY2008 · CA · contact PI
Bispecific Antibody Pretargeted Therapy of Pancreatic Cancer$319,025
R01 · FY2008 · CA · contact PI
Biospecific Antibody Pretargeting for NHL$100,586
P01 · FY2008 · CA · contact PI
Molecular Engineering and Antibody Production$68,304
P01 · FY2008 · CA · contact PI
Dosimetry$52,739
P01 · FY2008 · CA · contact PI
Bispecific Antibody Pretargeting for Therapy$477,990
R01 · FY2007 · CA · contact PI
Bispecific Antibody Pretargeted Therapy of Pancreatic Cancer$319,025
R01 · FY2007 · CA · contact PI
Bispecific Antibody Pretargeted Therapy of Pancreatic Cancer$328,553
R01 · FY2006 · CA · contact PI
Bispecific Antibody Pretargeting for Therapy$122,228
R01 · FY2006 · CA · contact PI
RAIT of Pancreatic Cancer with Humanized PAM4$886,058
R01 · FY2005 · CA
RAIT of Pancreatic Cancer with Humanized PAM4$866,940
R01 · FY2004 · CA
RAIT of Pancreatic Cancer with Humanized PAM4$624,927
R01 · FY2003 · CA
Improved Detection of Cancer Using Bi Specific Antibody$299,250
R01 · FY2003 · EB
Improved Detection of Cancer Using Bi Specific Antibody$256,500
R01 · FY2002 · CA
Improved Detection of Cancer Using Bi Specific Antibody$299,250
R01 · FY2001 · CA
CONSTRUCTION OF A MONOCLONAL ANTIBODY SUPPORT FACILITY$505,510
C06 · FY2000 · RR
IMPROVED SECOND ANTIBODY RADIOIMMUNOTHERAPY OF CANCER$442,644
R01 · FY2000 · CA
CORE--RADIOLABELING AND QUALITY ASSURANCE LABORATORY$292,374
P01 · FY2000 · CA
CORE--ANTIBODY PRODUCTION LABORATORY$292,374
P01 · FY2000 · CA
CLINICAL RADIOIMMUNODETECTION AND RADIOIMMUNOTHERAPY IN THE MANAGEMENT OF CANCER$292,374
P01 · FY2000 · CA
CORE--RADIOLABELING$0
P01 · FY2000 · CA
CORE--ANTIBODY PRODUCTION$0
P01 · FY2000 · CA